Symbols / EXAI
EXAI Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-11-08 06:00 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- Expert.ai (BIT:EXAI) Faces Deeper Losses Despite Revenue Forecasts of 18.9% Annual Growth - simplywall.st Fri, 03 Oct 2025 07
- Recursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug Discovery - Yahoo Finance Fri, 11 Oct 2024 07
- Exscientia stock rises on Recursion's buyout (NASDAQ:RXRX) - Seeking Alpha hu, 08 Aug 2024 07
- Exscientia Plc (EXAI): A Penny Stock That Will Make You a Millionaire - Yahoo Finance Sat, 31 Aug 2024 07
- Recursion and Exscientia Merger Approved by Shareholders - Nasdaq Wed, 13 Nov 2024 08
- Recursion and Exscientia. An AI Leader Emerges - Nanalyze Mon, 19 Aug 2024 07
- Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? - The Motley Fool Sun, 11 Aug 2024 07
- Exscientia is the Sniper of the AI Drug Discovery Industry - The Globe and Mail hu, 27 Jul 2023 07
- 3 Small-Cap Stocks With Explosive 2X Growth Potential - InvestorPlace Mon, 08 Jul 2024 07
- Exscientia Stock: Drug Discovery Platform Attracting Partners And Cash (NASDAQ:EXAI) - Seeking Alpha Wed, 22 May 2024 07
- The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. - The Motley Fool Sun, 18 Aug 2024 07
- Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? - Nasdaq Sun, 11 Aug 2024 07
- AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals - Yahoo Finance hu, 08 Aug 2024 07
- 3 AI Stocks Billionaires Are Loading Up On - InvestorPlace hu, 03 Aug 2023 07
- Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others (NASDAQ:EXAI) - Seeking Alpha hu, 08 Aug 2024 07
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for EXAI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|